Validation via Wnt agonists and the p53 inhibitor PFT-alpha revealed that MYCN activates the Wnt/beta-catenin/Fra-1 pathway by inhibiting DKK3 expression, ultimately inhibiting p53 activity and leading to the malignant progression of NB (Chen Y. et al., 2024). The gene discussed is TP53; the disease is neuroblastoma.